-
1Academic Journal
Συγγραφείς: V. В. Matveev, A. S. Olshanskaya, M. I. Volkova, В. Б. Матвеев, А. С. Ольшанская, М. И. Волкова
Πηγή: Cancer Urology; Том 15, № 3 (2019); 28-41 ; Онкоурология; Том 15, № 3 (2019); 28-41 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-3
Θεματικοί όροι: нежелательное явление, disseminated renal cell carcinoma, favorable and intermediate IMDC prognosis, METEOR phase III randomized clinical trial, adverse event, диссеминированный рак почки, хороший и промежуточный прогноз IMDC, рандомизированное клиническое исследование III фазы METEOR
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/983/866; National Comprehensive Cancer Network (2018). In: NCCN clinical practice guidelines in oncology (NCCN GuidelinesR) Kidney Cancer. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.; National Cancer Institute (2017). Surveillance, epidemiology, and end results program. In: National Comprehensive Cancer Network (ed.), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines R). Kidney Cancer v1. 2017. Bethesda, MD: National Cancer Institute, Surveillance Systems Branch.; Kovacs G., Akhtar M., Beckwith B.J. et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183(2):131–3. DOI:10.1002/(SICI)10969896(199710)183:23.0.CO;2-G.; Yagoda A., Petrylak D., Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am 1993;20(2):303–21.; Escudier B., Pluzanska A., Koralewski P. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103–11. DOI:10.1016/S0140-6736(07)61904-7.; Hudes G., Carducci M., Tomczak P. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271–81. DOI:10.1056/NEJMoa066838.; Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI:10.1056/NEJMoa065044.; Rini B.I., Halabi S., Rosenberg J.E. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422–8. DOI:10.1200/JCO.2008.16.9847.; Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061– 8. DOI:10.1200/JCO.2009.23.9764.; Носов Д.А., Воробьев Н.А., Гладков О.А. и др. Практические рекомендации по диагностике и лечению почечноклеточного рака. Злокачественные опухоли 2016;4(спецвыпуск 2):333–7.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;(Suppl 5):58– 68. DOI:10.1093/annonc/mdw328.; Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530–40. DOI:10.1200/JCO.1999.17.8.2530.; Motzer R.J., Bacik J., Murphy B.A. et al. Interferon alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289–96. DOI:10.1200/JCO.2002.20.1.289.; Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1803–13. DOI:10.1056/NEJMoa1510665.; Rini B.I., Halabi S., Rosenberg J.E. et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137–43. DOI:10.1200/JCO.2009.26.5561.; Figlin R.A., Hutson T.E., Tomczac P. et al. Overall survival with sunitinib versus interferon alfa as first-line treatment in metastatic renal-cell carcinoma. ASCO Annual Meeting Proceedings 2008. J Clin Oncol 2008;26(Suppl):abstr.5024.; Motzer R.J., Hutson T.E., Cella D. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722– 31.; Escudier B., Eisen T., Stadler W.M. et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312–8. DOI:10.1200/JCO.2008.19.5511.; Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372(9637):449–56. DOI:10.1016/S0140-6736(08)61039-9.; Rini B.I., Escudier B.J., Michaelson M.D. et al. Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. J Clin Oncol 2012;30(5_suppl):354.; NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 3.2019.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(5):706–20. DOI:10.1093/annonc/mdz056.; Guidelines on Renal Cell Carcinoma. European Association of Urology (EAU), 2018:34–40.; Yakes F.M., Chen J., Tan J. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298–308. DOI:10.1158/1535-7163.MCT-11-0264.; Katayama R., Kobayashi Y., Friboulet L. et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015;21(1):166–74. DOI:10.1158/1078-0432.CCR-14-1385.; Peltola K.J., Penttila P., Rautiola J. et al. Correlation of c-Met expression and outcome in patients with renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer 2017;15(4):487–94. DOI:10.1016/j.clgc.2017.01.021.; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499(7456):43–9. DOI:10.1038/nature12222.; Zhou L., Liu X.D., Sun M. et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016;35(21):2687–97. DOI:10.1038/onc.2015.343.; Nguyen L., Benrimoh N., Xie Y. et al. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs 2016;27(7):669–78. DOI:10.1097/CAD.0000000000000366.; Nguyen L., Holland J., Mamelok R. et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol 2015;55(11):1293–302. DOI:10.1002/jcph.526.; Kurzrock R., Sherman S.I., Ball D.W. et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660–6. DOI:10.1200/JCO.2010.32.4145.; Nguyen L., Holland J., Ramies D. et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol 2016;56(9):1130–40. DOI:10.1002/jcph.714.; Lacy S., Hsu B., Miles D. et al. Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos 2015;43(8):1190–107. DOI:10.1124/dmd.115.063610.; Choueiri T.K., Pal S.K., Mcdermott D.F. et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014;25(8):1603–8. DOI:10.1093/annonc/mdu184.; Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794–9. DOI:10.1200/JCO.2008.21.4809.; Choueiri T.K., Halabi S., Sanford B.L. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 2017;35(6):591–7. DOI:10.1200/JCO.2016.70.7398.; Choueiri T.K., Hessel C., Halabi S. et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progressionfree survival by independent review and overall survival update. Eur J Cancer 2018;94:115–25. DOI:10.1016/j.ejca.2018.02.012.; George D.J., Hessel C., Halabi S. et al. Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial. J Clin Oncol 2018;36(6):582. DOI:10.1200/JCO.2018.36.6_suppl.582.; Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814–23.; Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):917–27. DOI:10.1016/S1470-2045(16)30107-3.; Martínez Chanzá N., Xie W., Asim Bilen M. et al. Cabozantinib in advanced non-clearcell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet 2019;20(4):581–90. DOI:10.1016/S14702045(18)30907-0.; Powles T., Plimack E.R., Stus V. et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE426 study. J Clin Oncol 2019;37(suppl.7S):abstr.543.; Rini B., Plimack E.R., Stus V. et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019. DOI:10.1056/NEJMoa1816714. [Epub ahead of print].; Tannir M.N., Aren O., Hammers J.H. et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2019;37(suppl.7S):abstr.547.; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378(14):1277–90. DOI:10.1056/NEJMoa1712126.; Wallis C.J.D., Klaassen Z., Bhindi B. et al. First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analyses. Eur Urol 2018;74(3):309–21. DOI:10.1016/j.eururo.2018.03.036.; Rini B.I., Escudier B., Tomscak P. et al. Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011;378:1931–9.; Escudier B., Sharma P., McDermott D.F. et al. CheckMate 025 Randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017;72(6):962–71. DOI:10.1016/j.eururo.2017.02.010.; Волкова М.И., Евсюкова О.И., Ольшанская А.С., Матвеев В.Б. Первый опыт применения комбинации ленватиниба и эверолимуса при распространенном почечно-клеточном раке, резистентномк антиангиогенной терапии, в широкой клинической практике России. Онкоурология 2018;14(1):76–86. DOI:10.17650/1726-9776-2018-14-1-7686.; Wiecek W., Karcher H. Nivolumab versus cabozantinib: comparing overall survival in metastatic renal cell carcinoma. PLoS One 2016;11(6):e0155389. DOI:10.1371/journal.pone.0155389.; Amzal B., Fu S., Meng J. et al. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS One 2017;12(9):e0184423. DOI:10.1371/journal.pone.0184423.; Stukalin I., Wells J.C., Graham J. et. al. Realworld outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Curr Oncol 2019;26(2):e175–9. DOI:10.3747/co.26.4595.; Eichelberg C., Vervenne W., De Santis M. et al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinibsorafenib in the treatment of metastatic renal cell cancer. Eur Urol 2015;68(5):837–47. DOI:10.1016/j.eururo.2015.04.017.; Rexer H., AUO. First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 – AN 33/11). Urology 2014;53(5):735–8. DOI:10.1007/s00120014-3459-7.; Topalian S.L., Sznol M., McDermott D.F. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32(10):1020–30. DOI:10.1200/JCO.2013.53.0105.; Motzer R.J., Rini B.I., McDermott D.F. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33(13):1430–7. DOI:10.1200/JCO.2014.59.0703.; https://oncourology.abvpress.ru/oncur/article/view/983